Jonathan Mizrahi, MD

Articles

Dr. Mizrahi on Addition of PARP Inhibitors to Chemotherapy in Mutated Pancreatic Cancer

June 11th 2020

Jonathan Mizrahi, MD, discusses the addition of veliparib to chemotherapy in BRCA1/2 or PALB2-mutated pancreatic cancer.

Dr. Mizrahi on Targeting Treatment in Metastatic Colorectal Cancer

May 28th 2020

Jonathan Mizrahi, MD, discusses efforts being made to target treatment for patients with metastatic colorectal cancer.

Dr. Mizrahi on Optimal Sequencing in BRAF V600E-Mutant mCRC

March 26th 2020

Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.

Dr. Mizrahi on the Goal of the COMMIT Trial in dMMR Metastatic CRC

March 20th 2020

Jonathan Mizrahi, MD, discusses the goal of the phase III COMMIT trial in mismatch repair deficient colorectal cancer.

Dr. Mizrahi on Encouraging Trial Findings in mCRC

August 15th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses encouraging trial findings in metastatic colorectal cancer (mCRC).

Dr. Mizrahi on the Importance of Early Genomic Testing in CRC

May 15th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of early genomic testing in patients with colorectal cancer.

Dr. Mizrahi on the Importance of Personalized Care in mCRC

April 24th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of personalized care in patients with metastatic colorectal cancer.

Dr. Mizrahi on Bevacizumab as a Chemoprotectant in CRC

February 15th 2019

Jonathan Mizrahi, MD, hematology/oncology fellow, The University of Texas MD Anderson Cancer Center, discusses bevacizumab (Avastin) as a chemoprotectant in colorectal cancer (CRC).

x